Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis
- 29 January 2007
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (3), 376-385
- https://doi.org/10.1177/1352458506071213
Abstract
Objectives To determine if Ginkgo biloba (GB) improves the cognitive performance of subjects with multiple sclerosis (MS). Methods Randomized, double-blind, placebo-controlled trial of GB, 120 mg twice a day or placebo for 12 weeks. The primary outcomes were: the long delay free recall from the California Verbal Learning Test-II; the Paced Auditory Serial Addition Test; the Controlled Oral Word Association Test; the Symbol Digit Modalities Test; Useful Field of View Test; and the color-word interference condition from the Stroop Color and Word Test. Results On completion, the GB group (n=20) was 4.5 seconds (95% confidence interval (CI) (7.6, 0.9), P=0.015) faster than the placebo group (n=18) on the color-word interference condition of the Stroop test. Subjects who were more impaired at baseline experienced more improvement with GB (treatment*baseline interaction, F=8.10, P=0.008). We found no differences on the other neuropsychological tests. Subjects on GB reported fewer cognitive difficulties in the Retrospective Memory Scale of the Perceived Deficits Questionnaire than subjects on placebo (1.5 points, 95% CI (2.6, 0.3), P=0.016). No serious drug related side-effects occurred and GB did not alter platelet function assays. Conclusion Overall, GB did not show a statistically significant improvement in cognitive function. A treatment effect trend, limited to the Stroop test, suggests that GB may have an effect on cognitive domains assessed by this test, such as susceptibility to interference and mental flexibility. Multiple Sclerosis 2007; 13: 376-385. http://msj.sagepub.comKeywords
This publication has 25 references indexed in Scilit:
- Use and Self-Reported Benefit of Complementary and Alternative Medicine Among Multiple Sclerosis PatientsInternational Journal of MS Care, 2006
- Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant α1β2γ2L GABAA receptorsEuropean Journal of Pharmacology, 2004
- Neuroprotective effects of Ginkgo biloba extractCellular and Molecular Life Sciences, 2003
- Cognitive Dysfunction in Early-Onset Multiple SclerosisArchives of Neurology, 2001
- Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology?Medical Hypotheses, 2000
- Recent developments in the assessment of quality of life in Multiple Sclerosis (MS)Multiple Sclerosis Journal, 1999
- Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Platelet Activating Factor (PAF)Drugs, 1991
- Cognitive dysfunction in multiple sclerosis.Neurology, 1991
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961